Manuscript ID : 00001-44780

Source ID : 00000179

Journal of Cardiovascular Disease Research

Volume 12, Issue 4, 2021, Pages 1454-1504, Page Count - 51

LCMS/MS METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTIFICATION OF SIMEPREVIR IN HUMAN PLASMA.

Maddu Prasanthi [(1)] G.Gowrisankar [(2)*]

[(1)] Andhra University, Visakhapatnam, Andhra Pradesh, India.

[(2)] Andhra University, Visakhapatnam, Andhra Pradesh, India.

*** Corresponding author**

Abstract

To validate the procedure for estimation of Simeprevir Human K2EDTA plasma using LC-MS/MS. This study points to build up and validate a simple method logy to quantify the most used drug simeprevir for the treatment of hepatitis C virus (HCV) infection, in human plasma by using Simeprevir and Simeprevir-D6 as an internal Standard (IS) for preclinical studies a validated as per USFDA guidelines the determination of Amprenavir using an Quattro Premier XE LC-MS/MS coupled with 2695 HPLC separation module, a Xterra MS C18 (100 × 4.6 mm, 3.5µm) column and an SPD-M20A PDA detector.

Author Keywords

Acetonitrile,HPLC System,Nitrogen Evaporator, Human PlasmaPoly propylene tubes,Vibramax

ISSN Print: 0975-3583
ISSN Online: 0976-2833
Source Type: Journals
Document Type: Journal Article
Publication Language: English
DOI:
Abbreviated Journal Title: JCDR
Access Type: Open Access
Publisher Name: JCDR
Resource Licence: CC BY-NC
Major Subject: Health Sciences
Subject Area classification: Medicine
Subject area: Hematology
Source: SCOPEDATABASE